iHuman Inc. Files 6-K Report
Ticker: IH · Form: 6-K · Filed: Sep 27, 2024 · CIK: 1814423
Sentiment: neutral
Topics: 6-K, regulatory-filing
TL;DR
iHuman Inc. filed a 6-K, mostly a press release. Nothing major revealed.
AI Summary
iHuman Inc. filed a Form 6-K on September 27, 2024, reporting information for the month of September 2024. The filing includes a press release as Exhibit 99.1. Vivien Weiwei Wang, Director and Chief Financial Officer, signed the report on behalf of the company.
Why It Matters
This filing provides an update on iHuman Inc.'s regulatory disclosures, which is important for investors to stay informed about the company's ongoing reporting obligations.
Risk Assessment
Risk Level: low — This filing is a routine report of foreign private issuer and does not contain significant new financial or operational information.
Key Players & Entities
- iHuman Inc. (company) — Registrant
- Vivien Weiwei Wang (person) — Director and Chief Financial Officer
- September 27, 2024 (date) — Filing date
FAQ
What type of report is iHuman Inc. filing?
iHuman Inc. is filing a Form 6-K, which is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
What is the filing date of this report?
The filing date of this report is September 27, 2024.
Who signed the report on behalf of iHuman Inc.?
The report was signed by Vivien Weiwei Wang, Director and Chief Financial Officer.
What is the principal executive office address of iHuman Inc.?
The principal executive offices are located at Building A, No. 1 Wangjing East Road, Chaoyang District, Beijing 100102, People's Republic of China.
What exhibits are included with this 6-K filing?
The filing includes Exhibit 99.1, which is a Press Release.
Filing Stats: 150 words · 1 min read · ~1 pages · Grade level 10.2 · Accepted 2024-09-27 06:27:16
Filing Documents
- tm2425094d1_6k.htm (6-K) — 10KB
- tm2425094d1_ex99-1.htm (EX-99.1) — 170KB
- tm2425094d1_ex99-1sp1img001.jpg (GRAPHIC) — 2KB
- 0001104659-24-103361.txt ( ) — 185KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. iHuman Inc. By : /s/ Vivien Weiwei Wang Name : Vivien Weiwei Wang Title : Director and Chief Financial Officer Date: September 27, 2024